Dovepress

ORIGINAL RESEARCH

Long-Term Visual Function Effects of Pan-Retinal Photocoagulation in Diabetic Retinopathy and Its Impact in Real Life

Pedro Manuel Baptista [1,2]
Ana Ambrósio Marta [1,2]
João Heitor [1]
Diana José [1]
Daniel Almeida [1]
António Ribeiro [1]
Irene Barbosa [1,2]

[1]Ophthalmology Department, Centro Hospitalar Universitário do Porto, Porto, Portugal; [2]Instituto de Clências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal

Purpose: To address the long-term visual function after bilateral pan-retinal photocoagulation (PRP) and its impact in real life, namely on visual field (VF) legal criteria to drive. To determine potential predictors related to clinical factors and treatment strategies.

Patients and Methods: Observational cross-sectional study. Eyes from diabetic patients diagnosed with diabetic retinopathy who underwent bilateral PRP, with or without macular treatments and with visual acuity legal criteria for non-professional driving were randomly assigned. Main outcomes were: demographic and clinical data including best corrected visual acuity; binocular visual field (EBST-Esterman Binocular Suprathreshold Test, Humphrey analyzer3®); contrast sensitivity (CS-Metrovision-MonPack3®); light scattering in the retina (HD Analyzer, Visiometrics®).

Results: Seventy-one diabetic patients included (44 men and 27 women), with a mean age of 62.2±11.8 years. PRP was performed, on average, 9.7±6.9 years before the study. The average EBST Score was 85.8±17.0 and the average CS (2–5cpd) was 19.5±2.9 dB in photopic and 14.2±4.1 dB in mesopic conditions. Through a multivariate regression model, after adjusting to the clinical and demographic factors as possible confounders, we found that treatment factors associated with worse results were the use of Argon laser for the EBST Score, the very confluent PRP for the number of non-viewed points in the central 30°x20° of the EBST and the presence of macular treatments for the CS tests. According to Portuguese law, 79% (n=56) of patients had minimal EBST amplitudes for non-professional driving.

Conclusion: The functional results achieved in our sample are compatible with an active life, allowing most of the patients included to overcome the requirements of Portuguese legislation for driving light vehicles, namely at the level of the binocular visual field. These results highlight the role of PRP in the treatment of diabetic retinopathy in an era with evolving less aggressive laser options.

Keywords: diabetic retinopathy, pan-retinal photocoagulation, retinal laser, Esterman binocular visual field, contrast sensitivity

Introduction

Pan-retinal photocoagulation (PRP) has become the gold standard for the treatment of proliferative diabetic retinopathy (PDR) since 1976, by the time the Diabetic Retinopathy Study Research Group[1] demonstrated a reduction in the rate of visual loss with laser treatment. Thereafter, several analyses[2–5] were conducted by the same scientific group in order to evaluate the structural and functional results. Despite having demonstrated its effectiveness, they highlighted the harmful

Correspondence: Pedro Manuel Baptista
Centro Hospitalar Universitário do Porto, Largo Prof. Abel Salazar, Porto, 4099-001, Portugal
Email pedroyybaptista@gmail.com

potential to the retinal and choroidal tissues, with risk of functional impact, particularly on visual fields (VF).

The evolution of lasers from conventional to a diversity of multispot and subthreshold systems, capable of reducing exposure times and using different wavelengths with different absorption spectra, has increased the options of treatment strategies, presenting different potential for harm and theoretically less impact on daily life activities;[6] however, data available in the literature regarding the effects of PRP is limited mainly due to small sample sizes, short follow-up periods and the evaluation of treatments with non-standardised parameterizations.

In practice, PRP can have a real functional impact and be a handicap in daily living for active people, particularly driving. Acquiring and maintaining the driving license has long been a concern for the population with DR undergoing bilateral PRP,[7–12] and this may be, at the same time, a way to address the functional results of the procedure in real-life studies. Visual acuity is the major, and most of the times, inadequately the only requirement for maintaining driving license. However, even individuals with good central vision in photopic conditions can have impairment in other important visual functions like night vision or visual field. In this sense, the main purpose of the present work is to quantify in a more comprehensive way the visual function of patients submitted to bilateral PRP and with visual acuity legal criteria to drive light vehicles and address its impact in real life. Additionally, we aimed to built a multivariable regression model to determine potential independent predictors of these functional outcomes related to clinical factors and treatment strategies.

Patients and Methods
Design
Observational cross-sectional study set at the Ophthalmology Department, Centro Hospitalar e Universitário do Porto, Porto, Portugal, a tertiary center. The study followed the tenets of the Declaration of Helsinki. Approval was obtained from the "Departamento de Ensino, Formação e Investigação" (DEFI), no. 144-20 (114-DEFI/116-CE). Written informed consent was waived due to total anonymization and confidentiality of the data and the absence of detailed individual clinical information.

Population
Diabetic patients diagnosed with DR and submitted to bilateral PRP with or without macular and/or focal photocoagulation in the posterior pole. The criterion for patient selection was minimum visual acuity for driving light vehicles (group 1), according to Decree-Law no. 40, 07/29/2016:[13] binocular visual acuity of at least 0.5 (decimal), with or without optical correction, or visual acuity of at least 0.6 (decimal), with or without optical correction, in cases of monocularity. The presence of corneal diseases, concurrent macular diseases, in-treatment active macular edema,[14] optic nerve diseases other than glaucoma, history of amblyopia and impaired ability to perform functional tests due to neurological or psychiatric status were considered exclusion criteria.

Laser Treatments
Treatments were performed with Argon (514 nm) (Coherent®) and Double frequency nd:YAG monospot (nd:YAGII) (532 nm) (ZEISS®) and multispot (Valon®) lasers. The most frequently used timing was 100 ms for the Argon laser, and 20–30 ms for the nd:YAGII. The spot size used was 50 or 100 µm for the macular or focal photocoagulation at the posterior pole, 200 to 250 µm for the photocoagulation adjacent to vascular arcades, and 200 to 500 µm in the periphery, depending on the media opacity and magnification of the contact lenses used, among other factors. The contact lenses used for the treatments were: Mainster focal lens (Ocular®) for macular photocoagulation, in the posterior pole and adjacent to the vascular arcades and panfundoscopic lens, namely, Mainster lens PRP 165 (Ocular®) and 3 mirror lens (Ocular®) for photocoagulation of the peripheral retina. The power applied was selected in order to allow visualization of the whitish marks resulting from the impacts on the retina.

Data Gathering
Demographic and clinical data were obtained through analysis of patients' clinical records. Data were collected regarding: age; gender; type and duration of diabetes (tD); duration of the DR (tDR); best corrected visual acuity, at a distance of 6 meters, on the decimal scale (BCVA); lens status; history of diabetic macular edema (DME) and/or intravitreal injections of anti-vascular endothelial growth factor (VEGF) or corticosteroids; history of glaucoma or ocular hypertension (OHT); concomitance of pathology or previous vitreoretinal (VR) surgery; history of peripheral retinal cryoablation (PRC); type of laser; time since PRP (tPRP).

Retinal photocoagulation characteristics were obtained by analysing all clinical records, retinographs and previous

angiographies, all recorded by the same physician. Regarding PRP, three patterns were considered, according to the predominance of the following aspects: non-confluent, when the marks of the various impacts were observed individually, with spacing between them greater than one-mark size; confluent, when this spacing was equal or less than one-mark size; very confluent, when there was coalescence of the various marks. Additionally, the quantification of the total treated area was calculated based on the sum of the various impacts made in different photocoagulation sessions, with reduction of the various spot sizes to a 250 μm spot size area. Photocoagulation within the posterior pole was divided into two categories: focal and in the form of a macular temporal horseshoe (modified macular grid), always preserving the papillomacular bundle. Figure 1 shows examples of different combinations of peripheral and macular treatment patterns.

Visual function was assessed in different ways other than the BCVA: visual field (VF), contrast sensitivity (CS) and retinal light scattering. The VF was analysed using the Esterman Binocular Suprathreshold Test (EBST) (Humphrey Analyzer3®; central fixation target, white III stimulus, 31.5 asb background, two zone strategy, age-corrected, central and peripheral references of 34 dB) by measuring the amplitudes in each direction, the Esterman Efficiency Score (EES) and the number of non-viewed points within the central square of the horizontal 30° and vertical 20° (NVP30°x20°) and in each quadrant. Regarding the CS, we analysed the function both under photopic (PCS) and mesopic conditions (MCS) in the various spatial frequencies (Metrovision-MonPack3®; static, grating luminance's of 80 cd/m² in the photopic exam and 0.08 cd/m² in the low mesopic exam). Through the HD Analyser® technology, light scattering was objectively measured across the ocular media (Objective Scatter Índex, OSI) and ocular contrast sensitivity function without optic nerve and cortical compounds was addressed

Figure 1 Examples of treatment patterns. (**A–C**) patient 1; (**D**) and (**E**) patient 2; (**F**) patient 3. (**A**) Fundus photography; (**B**) macular temporal horseshoe, fluorescein angiography; (**C**) confluent PRP pattern, fluorescein angiography; (**D**) fundus photography; (**E**) very confluent PRP pattern, fluorescein angiography; (**F**) macular focal treatment, fluorescein angiography.

(Modular Transfer Function, MTF), both for a pupil size of 4 mm.

Real-Life Impact Measurement

The impact of PRP on real life was assessed evaluating the interference of the binocular visual field test with the ability to drive light vehicles. According to the aforementioned Decree-Law, the visual field must meet the following requirements: be at least 120° in the horizontal plane and have a minimum extension of 50° to the left and right, and 20° to the top and bottom, and the absence of defects within a radius of 20° from the central axis.

Statistical Analysis

All analyses were performed using the SPSS® and Stata® softwares. Data normality was tested with Shapiro–Wilk and Kolmogorov–Smirnov tests. Levene's test was applied to assess homogeneity of variances. When parametric analysis could be applied, the Student's t-test was used to compare the variables. When nonparametric tests were needed, the Wilcoxon rank-sum test was applied. The $\chi2$ was used to compare nominal and ordinal variables. Spearman's rank correlation coefficient was used to correlate variables.

The candidate predictors in multivariable analyses were treatment characteristics and patients' demographic and clinical factors. Predictors were screened in order to identify associations with BCVA, EES, NVP30°x20°, PSC and MCS at the $p<0.25$ level. Predictors meeting this criterion were included in a stepwise, backward analysis in which $p<0.05$ served as the criterion for inclusion into the full model– exceptions were made when clinically appropriate.

All values are shown as mean ± standard deviation unless otherwise specified. All p-values (p) were 2-sided, and p-values <0.05 were considered significant.

Results

Demographics and General Descriptions

The study population consisted of 142 eyes of 71 diabetic patients who underwent PRP, divided into 44 (62%) men and 27 (38%) women, with a mean age of 62.2±11.8 [38–86] years. As for the type of disease, 29 (41%) had type 1 and 42 (59%) had type 2 diabetes. The Argon laser (514 nm) was used in the majority (63%, n=89) of eyes. The most common PRP pattern was the confluent (73%, n=104) and the majority (85%, n=120) of eyes underwent posterior pole laser treatments. Clinical, demographic and treatment data are in Tables 1 and 2.

Visual Acuity

The mean of BCVA was 0.71, with 62 (44%) of the eyes reaching 0.8 or better on the decimal scale. Eyes with cataract (p=0.010) had lower BCVAs. There were no significant differences within the different treatment subgroups (p>0.05) (Tables 3 and 4). Higher age was associated with lower BCVA (r=−0.408, p<0.001).

Visual Field

The averages of both the visual field amplitudes and the non-viewed points in each quadrant on the EBST are within Figure 2. The average EES achieved was 85.8 ±17.0 and the average of points seen was 103.8±20.0 out of 120 possible.

Patients treated with Argon laser (p<0.001), those treated with very confluent pattern (p<0.001) and patients with history of VR surgery (p=0.001) or PRC (p=0.008) obtained significantly lower EES (Tables 3 and 4). A lower EES was negatively correlated with higher age (r=−2.47, p=0.003), tD (r=−0.356, p<0.001), tDR (r= −0.431, p<0.001) and tPRP (r=0.510, p<0.001).

Centering the analysis on the macular area, the mean NVP30°x20° was 1.9±4.4 within 54 possible. The groups with Argon Laser (p=0.001) and very confluent PRP pattern (p<0.001) had higher values. On the other hand, the macular treatment characteristics did not influence significantly the outcome (p>0.05). History of VR surgery (p=0.005) was the only clinical factor associated with a higher value (Tables 3 and 4). The NVP30°x20° was positively correlated with tD (r=0.337, p<0.001), with tDR (r=0.445, p<0.001), with tPRP (r=0.516, p<0.001) and the number of impacts (r=0.212, p=0.013).

Contrast Sensitivity

The curves obtained through the average values of the PCS and MCS in each special frequency range are shown in Figure 3. Overall, the loss tended to be greater at higher spatial frequencies, both in photopic and mesopic conditions.

In the analysis centered on the 2–5cpd interval, near normal PCS (19.5±2.9 dB) and subnormal MCS (14.2±4.1 dB) on average were found. In the PCS test, eyes treated with Argon laser (p=0.033), those who had macular treatments (p<0.001) and eyes with cataract (p=0.005) had lower values. In the MCS, eyes who had macular

Table 1 Clinical and Demographic Data: Overall and per Type of Diabetes Analysis

	All Sample 142 Eyes	T1 58 Eyes	T2 84 Eyes	T1 vs T2 (p)
Age (years)	62.2 ± 11.8	53.1 ± 10.6	68.4 ± 8.1	<0.001
tD (years)	32.7 ± 8.6	36.0 ± 7.8	30.5 ± 8.5	<0.001
tDR (years)	18.1 ± 8.7	21.8 ± 9.0	15.5 ± 7.5	<0.001
tPRP (years)	9.7 ± 6.9	12.3 ± 8.3	7.8 ± 5.0	<0.001
250 µm Spots (nr)	5825 ± 2353	6581 ± 2700	5263 ± 1889	0.002
Lens status, n (% within group)				
Transparent	24 (17%)	20 (34%)	4 (5%)	<0.001
Cataract	50 (35%)	21 (36%)	29 (35%)	0.86
Pseudophakic	68 (48%)	17 (29%)	51 (61%)	<0.001
Ophthalmological history, n (% within group)				
OHT/Glaucoma	27 (19%)	8 (14%)	19 (23%)	0.19
DME	46 (32%)	14 (24%)	32 (38%)	0.081
Anti-VEGF/Corticosteroid	15 (11%)	2 (3%)	13 (15%)	0.026
VR pathology	40 (28%)	18 (31%)	22 (26%)	0.40
ERM	19	5	14	
VH	14	8	6	
RD	6	5	1	
MH	1	0	1	
VR surgery	23 (16%)	13 (22%)	10 (12%)	0.095
PRC	17 (12%)	11 (19%)	6 (7%)	<0.001

Notes: Statistical significance at p<0.05. T1: type 1 diabetics, T2: type 2 diabetics, tD: time since diabetes diagnosis, tD: time since diabetic retinopathy diagnosis.
Abbreviations: tPRP, time since pan-retinal photocoagulation; OHT, ocular hypertension; DME, diabetic macular edema; Anti-VEGF, anti-vascular endothelial growth factor and/or corticosteroids; VR, vitreo-retinal; ERM, epiretinal membrane; VH, vitreous hemorrhage; MH, macular hole; PRC, peripheral retinal cryoablation.

Table 2 Photocoagulation Treatment Data: Overall and per Type of Diabetes Analysis

	All Sample 142 Eyes	T1 58 Eyes	T2 84 Eyes	T1 vs T2 (p)
Type of laser, n (% within group)				
Argon	89 (63%)	42 (72%)	47 (56%)	0.046
nd:YAGII	53 (37%)	16 (28%)	37 (44%)	
Pattern of PRP, n (% within group)				
Non-confluent	2 (1%)	0 (0%)	2 (2%)	0.31
Confluent	104 (73%)	40 (69%)	64 (76%)	
Very confluent	36 (25%)	18 (31%)	18 (21%)	
Macular treatments, n (% within group)				
No treatment	22 (16%)	13 (22%)	9 (11%)	0.15
Focal	62 (44%)	22 (38%)	40 (48%)	
Modified grid	58 (41%)	23 (40%)	35 (42%)	

Note: Statistical significance at p<0.05.
Abbreviations: Argon, Argon laser (514 nm, Coherent®); nd:YAGII: Double frequency nd:YAG (532 nm) monospot (ZEISS®) and multispot (Valon®) lasers.

Table 3 Overall and per Laser Treatment Subgroup Analysis

	BCVA (Decimal)		EES		NVP (20°X30°)		PCS 2–5cpd (dB)		MCS 2–5cpd (dB)		OSI		MTF	
	Mean ± SE	p	Mean ± SE	p	Mean ± SE	p	Mean ± SE	p	Mean ± SE	p	Mean ± SE	p	Mean ± SE	p
All sample	0.71 ± 0.24		85.8 ± 17.0		1.9 ± 4.4		19.5 ± 2.9		14.2 ± 4.1		2.7 ± 3.0		27.3 ± 13.2	
Type of Laser														
Argon (514nm)	0.70 ± 0.24	0.698	81.5 ± 18.0	<0.001	2.7 ± 5.2	0.001	19.1 ± 3.1	0.033	14.0 ± 4.1	0.306	3.1 ± 3.2	0.056	25.0 ± 13.1	0.009
nd: YAGII (532nm)	0.72 ± 0.27		93.0 ± 12.0		0.6 ± 1.8		20.1 ± 2.6		14.7 ± 4.0		2.1 ± 2.5		31.0 ± 12.6	
PRP pattern														
Laser Confluent	0.71 ± 0.25	0.812	89.6 ± 13.5	<0.001	1.0 ± 3.4	<0.001	19.7 ± 2.9	0.084	14.2 ± 4.3	0.842	2.7 ± 3.2	0.831	28.3 ± 14.0	0.094
Laser Very confluent	0.70 ± 0.26		73.9 ± 20.6		4.8 ± 5.6		18.7 ± 3.0		14.4 ± 3.5		2.8 ± 2.2		24.6 ± 10.6	
Macular treatments														
Yes	0.70 ± 0.25	0.452	86.7 ± 15.9	0.238	1.8 ± 4.4	0.441	19.0 ± 2.8	<0.001	13.7 ± 3.9	<0.001	2.8 ± 3.1	0.476	27.0 ± 13.2	0.633
No	0.75 ± 0.24		80.9 ± 21.5		2.6 ± 4.2		22.1 ± 2.3		17.1 ± 4.0		2.3 ± 1.9		28.5 ± 13.8	
Macular treatment pattern														
Focal	0.70 ± 0.25	0.825	84.4 ± 15.5	0.112	2.4 ± 4.6	0.161	18.9 ± 2.5	0.874	13.4 ± 2.9	0.356	3.0 ± 3.5	0.448	27.2 ± 13.4	0.922
Modified Grid	0.71 ± 0.25		89.1 ± 16.2		1.2 ± 4.2		19.0 ± 3.1		14.0 ± 4.8		2.5 ± 2.7		26.9 ± 13.0	

Note: Statistical significance at p<0.05.
Abbreviations: BCVA, best corrected visual acuity; EES, Esterman Efficiency Score; NVP30°x20°, number of non-viewed points within the central square of the horizontal 30° and vertical 20°; PCS, photopic contrast sensitivity; MCS, mesopic contrast sensitivity; OSI, Objective Scatter Index; MTF, Modular Transfer Function; Argon, Argon laser (514nm, Coherent®); nd:YAGII: Double frequency nd:YAG (532nm) monospot (ZEISS®) and multispot (Valon®) lasers; PRP, pan-retinal photocoagulation.

Table 4 Overall and per Clinical and Demographic Subgroup Analysis

	BCVA (Decimal)		EES		NVP (20°X30°)		PCS 2–5cpd (dB)		MCS 2–5cpd (dB)		OSI		MTF	
	Mean ± SE	p	Mean ± SE	p	Mean ± SE	p	Mean ± SE	p	Mean ± SE	p	Mean ± SE	p	Mean ± SE	p
All sample	0.71 ± 0.24		85.8 ± 17.0		1.9 ± 4.4		19.5 ± 2.9		14.2 ± 4.1		2.7 ± 3.0		27.3 ± 13.2	
Type of diabetes														
1	0.79 ± 0.24	0.001	82.0 ± 19.7	0.038	2.2 ± 4.6	0.481	19.7 ± 3.6	0.457	15.4 ± 4.3	0.005	2.6 ± 3.3	0.794	29.1 ± 13.9	0.170
2	0.66 ± 0.24		88.4 ± 14.3		1.7 ± 4.2		19.3 ± 2.4		13.4 ± 3.7		2.8 ± 2.8		26.0 ± 12.7	
Lens status														
Transparency + Pseudophaquic	0.75 ± 0.24	0.010	84.2 ± 18.6	0.100	2.5 ± 5.1	0.064	20.0 ± 2.7	0.005	14.8 ± 3.3	0.045	2.0 ± 1.7	0.002	30.3 ± 12.0	<0.001
Cataract	0.64 ± 0.25		88.64 ± 13.1		1.9 ± 2.0		18.5 ± 3.1		13.2 ± 5.0		4.0 ± 4.2		21.7 ± 13.7	
DME														
Yes	0.66 ± 0.25	0.084	88.1 ± 18.0	0.264	1.7 ± 4.8	0.602	18.8 ± 2.3	0.032	13.8 ± 3.0	0.303	2.3 ± 1.6	0.157	26.6 ± 10.7	0.658
No	0.73 ± 0.24		84.7 ± 16.4		2.1 ± 4.2		19.8 ± 3.2		14.4 ± 4.5		2.9 ± 3.4		27.6 ± 14.3	
OHT/Glaucoma														
Yes	0.68 ± 0.22	0.474	80.3 ± 19.5	0.107	2.8 ± 3.8	0.285	20.3 ± 1.9	0.038	15.1 ± 4.1	0.229	2.8 ± 1.8	0.800	24.5 ± 12.6	0.220
No	0.72 ± 0.26		87.0 ± 16.1		1.7 ± 4.5		19.3 ± 3.1		14.0 ± 4.1		2.7 ± 3.2		27.9 ± 13.3	
VR surgery														
Yes	0.66 ± 0.25	0.319	69.4 ± 22.3	<0.001	5.4 ± 6.2	0.005	18.7 ± 2.4	0.179	14.7 ± 3.5	0.510	2.7 ± 2.3	0.982	24.8 ± 11.3	0.322
No	0.72 ± 0.25		88.9 ± 13.7		1.3 ± 3.6		19.6 ± 3.0		14.1 ± 4.2		2.7 ± 3.1		27.8 ± 13.5	
PRC														
Yes	0.67 ± 0.25	0.430	71.1 ± 22.3	0.008	4.6 ± 6.0	0.061	19.9 ± 3.4	0.499	16.8 ± 4.4	0.005	2.3 ± 1.2	0.298	24.0 ± 11.1	0.208
No	0.72 ± 0.25		87.8 ± 15.3		1.6 ± 4.0		19.4 ± 2.9		13.9 ± 3.9		2.8 ± 3.2		27.8 ± 13.5	

Note: Statistical significance at p<0.05.
Abbreviations: BCVA, best corrected visual acuity; EES, Esterman Efficiency Score; NVP30°x20°, number of non-viewed points within the central square of the horizontal 30° and vertical 20°; PCS, photopic contrast sensitivity; MCS, mesopic contrast sensitivity; OSI, Objective Scatter Index; MTF, Modular Transfer Function; DME, diabetic macular edema; OHT, ocular hypertension; VR, vitreo-retinal; PRC, peripheral retinal cryoablation.

Figure 2 Example of an Esterman binocular visual field test printout. Green squares: mean visual field amplitudes (°) of the sample; red circles: average non-viewed points per quadrant, in all sample.


Figure 3 Example of a theoretical contrast sensitivity (dB) curve in photopic (**A**) and mesopic (**B**) conditions. Green line: normal theoretical curve; green, orange and red squares: mean values (dB) of the sample in each spatial frequency interval.

treatments (p<0.001) and those with history of PRC (p=0.005) or presence of cataract (p=0.045) had lower values (Tables 3 and 4). Lower PCS and MCS in the 2–5cpd interval were associated with higher age (r=−0.232, p=0.005 and r=−0.343, p<0.001, respectively) and OSI (r=−0.358, p<0.001 and r=−0.376, p<0.001, respectively) and lower BCVA (r=0.445, p<0.001 and r=0.417, p<0.001, respectively) and MTF (r=0.335, p<0.001 and r=0.362, p<0.001, respectively) values.

Light Scattering

Patients reached global mean values of 2.7±3.0 in the OSI and 27.3±13.2 in the MTF. Eyes with cataract had higher mean OSI values (p=0.002) and lower MTF (p<0.001). Eyes treated with Argon laser had lower MTF (p=0.009) (Tables 3 and 4). Higher OSI and lower MTF were associated with older age (r=0.395, p<0.001 and r=−0.279, p=0.001, respectively) and with higher tPRP (r=0.240, p=0.004 and r=−0.178, p=0.036, respectively).

Comparison by Type of Diabetes

Patients with type 1 diabetes were younger but had longer tD (p<0.001), tDR (p<0.001) and tPRP (p<0.001) and higher number of spots (p=0.002) and PRC history (p<0.001). The proportion of eyes with cataracts was similar in the two groups (p=0.86) but more eyes underwent anti-VEGF within type 2 group (p=0.026). The proportion of eyes who underwent Argon laser treatments was higher within type 1 diabetics (p=0.046) (Tables 1 and 2). Assessing the functional results, eyes from type 1 diabetics had higher BCVA (p=0.001) and MCS (p=0.005), but lower EES (p=0.038) (Tables 3 and 4).

Multivariable Regression Analysis

A multivariable regression model was built to determine potential independent predictors of the functional outcomes and adjust for potential confounders (Table 5). Older age and cataract were independent predictors for worse BCVA. Older age, type 1 diabetes, Argon laser therapy, history of PRC or VR surgery were independent predictors for lower EES. Older age, history of PRC and very confluent PRP pattern were independent predictors of higher NVP30°x20°. Older age, presence of cataract, the number of spots and macular treatments were independent predictors for lower PCS 2–5cpd and MCS 2–5cpd. Additionally, history of VR surgery or OHT/Glaucoma were independent predictors only for the PCS 2–5cpd.

Neither tD, tDR or tPRP were independent predictors of the functional outcomes.

Discussion

The present work is a real-world study, which is aimed to expose the real-life functional results of bilateral PRP nearly 10 years after the treatment in average. Because DR and DME share most of risk factors,[15] eyes with PDR are more prone to develop DME with need of intravitreal treatments and, not rarely, more invasive treatments like PRC or VR surgery. Additionally, the higher prevalence of glaucoma in PDR eyes has been reported many years ago.[16] Thus, the authors did not exclude these eyes as it could preclude the aimed real-life analysis. However, patients without the minimum legal BCVA requirements to drive were excluded for three reasons: first, after analyzing the initial sample, those patients were found to have high proportion of concurrent important factors that could skew the results of CS and VF, like dense cataracts, chronic DME with external retinal impairment or terminal neovascular glaucoma; second, most of these problems are related to the natural history and degree of the disease itself, being confounding factors; third, most had other cardiovascular/cerebrovascular comorbidities with decreased capability of performing the visual tests.

In fact, even after the application of the inclusion and exclusion criteria, the prevalence of some clinical confounders in the sample is of notice, namely cataract (35%), history of DME (32%). In the comparative analysis, worse results were found in eyes with cataract regarding BCVA, light scattering, and contrast sensitivity functions but only regarding PCS in eyes with DME history. This highlight the complexity of these patients and the need of an adjusted analysis when the aim is to find treatment-related predictors of prognosis.

The sample presented very good results regarding BCVA, with approximately 44% of eyes reaching a BCVA of 0.8 or more; however, one should keep in mind that patients with low BCVA not compatible with the legal title for driving non-professional vehicles were excluded, as aforementioned. However, it should be highlighted that no treatment-related factors were associated with significant differences after the adjustment for cataract and age as confounders.

The global average of OSI was only slightly lower than the normal reference intervals. After adjusting for cataract as a confounder, we could infer that laser treatments do not

Table 5 Multivariable Regression Model

	BCVA (Decimal)		EES		NVP30°x20°**		Photopic CS 2–5cpd (dB)		Mesopic SC 2–5cpd (dB)	
	R² 22.1%	RMSE 0.22	R² 38.5%	RMSE 13.4	R² 21.5%	RMSE 0.86	R² 32.5%	RMSE 2.5	R² 31%	RMSE 3.4
	Coefficient ± SE	P	Coefficient ± SE	P	Coefficient ± SE	P	Coefficient ± SE	P	Coefficient ± SE	P
Type of Laser										
Argon (514nm)	Reference		Reference		Reference		Reference		Reference	
nd:YAGII (532nm)		NS	8.5 ± 2.6	0.001		NS		NS		NS
PRP pattern										
Laser Confluent	Reference		Reference		Reference		Reference		Reference	
Laser Very confluent		NS		NS	1.69 ± 1.26**	0.027		NS	(−)3.7 ± 0.9	<0.001
Macular treatments		NS		NS		NS		NS		NS
Macular treatment pattern										
No treatment	Reference		Reference		Reference		Reference		Reference	
Focal		NS		NS		NS	(−)2.9 ± 0.7	<0.001		NS
Modified Grid		NS		NS		NS	(−)3.0 ± 0.7	<0.001		NS
250μm Spots (nr)		NS				NS	(−)0.0003 ± 0.0001	0.011	(−)0.0004 ± 0.0001	0.006
Clinical and demographic factors										
Type of diabetes										
1	Reference		Reference		Reference		Reference		Reference	
2	(−)0.13 ± 0.03	0.001	11.2 ± 3.1	0.001		NS		NS		NS
Cataract		NS		NS		NS	(−)1.7 ± 0.5	<0.001	(−)1.4 ± 0.9	<0.001
PRC		NS	(−)10.0 ± 3.8	0.010	1.86 ± 1.33**	0.002		NS		NS
DME		NS		NS				NS		NS
OHT/Glaucoma		NS		NS		NS	(−)1.6 ± 0.6	0.005		NS
VR surgery		NS	(−)11.7 ± 3.4	0.001		NS	(−)2.0 ± 0.6	0.001		NS
Age (years)	(−)0.009 ± 0.02	<0.001	(−)0.61 ± 0.13	<0.001	1.04 ± 1.01**	0.022	(−)0.07 ± 0.02	<0.001	(−)0.12 ± 0.03	<0.001
tD (years)		NS				NS		NS		NS
trD (years)		NS				NS		NS		NS
tPRP (years)		NS				NS		NS		NS

Notes: **A logarithmic transformation was performed for this variable. The coefficients are presented as exp(b). tD: time since diabetes diagnosis, tD: time since diabetic retinopathy diagnosis. Statistical significance at p<0.05.
Abbreviations: BCVA, best corrected visual acuity; EES, Esterman Efficiency Score; NVP (20°X30°), non-viewed points within the central 20°X30° visual field area; CS, contrast sensitivity; OSI, objective scatter index; Argon, Argon laser (514nm, Coherent®); nd:YAGII, Double frequency nd:YAG (532nm) monospot (ZEISS®) and multispot (Valon®) lasers; PRP, pan-retinal photocoagulation; PRC, peripheral retinal cryoablation; DME, diabetic macular edema; OHT, ocular hypertension; VR, Vitreo-retinal; tPRP, time since pan-retinal photocoagulation.

interfere significantly with the refractive performance of ocular media.

Concerning EBST, very acceptable results were found at average amplitudes and each quadrant presented only mild localised sensitivity losses. The EES was found at the highest quartile of normality and, after adjusting for age and history of VR surgery or PRC as confounding factors, Argon laser treatment was the only PRP factor associated with worse results. In the macular area, overall, the number of NVP30°x20° was low. After the adjustment for age and history of PRC as confounders, the only treatment-related factor associated with worse outcomes was the very confluent PRP pattern. Despite the general idea of VF loss after PRP, there is no consensus in literature. In a study with a small population (10 eyes), there were no negative effects of treatment regarding VF in the short term (6 months).[7] On the other hand, in a recent prospective 2-year study, Filek et al[17] described a significant loss in VF evaluation in 16 patients undergoing PRP. In the scientific literature, no studies comprising long-term results in a large sample were found, as in the present study.

However, when translating these results into a quantifiable real-life parameter and according to the Decree-Law[13] already stated, 15 (21%) patients did not present minimum amplitudes of VF for driving non-professional light vehicles, on average after almost a decade of tPRP, in agreement with a series of 100 patients evaluated by Mackie et al.[11] Several countries have contributed with studies in these populations and there seems to exist important legal differences to highlight: in the USA, not all states share the mandatory measurement of CV,[3] while in the United Kingdom patients undergoing PRP are required to inform the Driver and Vehicle Licensing Agency (DVLA).[11] Many studies showed variable results in relation to the failure rate, regarding the minimum requirements by the DVLA (12–50%), justifiable by the type of laser used, parameterization of the power, exposure time and spot size, and lens magnification.[7–10,18]

Higher age was found to be a confounder for worse visual function results in all of evaluated parameters. With increasing life expectancy and the associated increase in prevalence of DR, more diabetics with PRP are expected to have systemic health conditions compatible with an active life and, therefore, this area of study will be of particular relevance and the negative effects of age should not be neglected.

The present study demonstrates the maintenance of PCS averages curve nearly in the lower limit of the reference interval but the MCS averages curve significantly under the reference interval, a decade after the treatment. In the same way as for VF, there is controversy in the literature about the deterioration of CS in patients undergoing PRP and there is lack of studies with long-term results and large sample sizes. In the 1990s, Mackie et al[19] illustrated impairment in CS, in a cross-sectional study. On the other hand, Khosla et al[20] prospectively demonstrated an initial but time-limited deterioration in the first three months. More recently, Preti et al[21] corroborate these results, with stabilization at 6 months and demonstrate that adjuvant intravitreal treatment with Bevacizumab can be a protective factor, namely by decreasing DME. In the present study, the possible confounders were age and the presence of cataract for both PCS and MCS in the 2–5cpd interval and the history of OHT/Glaucoma or VR surgery only for the PCS. After the adjustment, and contrary to PRP patterns, the number of spots and the macular treatments were the only PRP-related factors associated with worse outcomes.

The significant number of type 1 diabetics in the present study deserved an individual analysis. After adjusting for the different clinical and treatment characteristics described above, type 1 diabetes predicted only worse EES and this reinforces the favorable risk-benefit ratio in carrying out these treatments at an early age in DR, which is known to be more aggressive in type 1 diabetic patients.

The main strengths of the present study are the large sample size, the long time since PRP and the proportion of type 1 diabetic patients. The exclusion of patients which did not met the visual acuity criteria for driving according to the Portuguese law is the major limitation. However, the authors found it as the more reasonable way to expose a real-life analysis of visual function other than the central visual acuity measured in optimized conditions and at the same time highlighting the inclusion of these tests as pivotal for a thorough analysis in PRP patients. The retrospective nature, lack of baseline data or a control group could be understood as another two limitations of the study. However, regarding the second, some visual function tests described are not indicated for routine practice and would not be possible to perform some years ago in many patients included; regarding the third, as PRP is the gold standard since 1976, with no other approved therapeutic option, and

non-treatment not being an option, it would always be impossible to make a comparison with a control group with such a large follow-up since PRP.

With the increase in life expectancy of patients with DR, it is important to address the long-term treatment burden they will bring to healthcare services. Thus, when the PRP strategy as primary treatment for proliferative DR is compared prospectively with a strategy based on anti-VEGF intravitreal injections, despite worse functional results in the PRP group reported at two years,[22] a recent cost-effectiveness study[23] point to an 85–90% decrease in cost-utility, extrapolated to the average 30-year life expectancy in these patients. In the present study, it is relevant to state that tD, tRD and, particularly, tPRP were not predictors of worse outcomes.

The present study includes eyes treated many years ago using conventional lasers with high temporizations and energies, within large retinal areas. By demonstrating good adjusted functional long-term results with these aggressive treatments our study values the role of PRP as a safe and cost-effective strategy to treat this increasing public health problem, in the present and future era of modern laser options and new tailored treatment strategies, less aggressive to retinal tissue.[24]

Conclusion

Pan-retinal photocoagulation can be considered an effective and safe treatment for long-term stabilization of diabetic retinopathy. Despite the retinal tissue aggression inherent to the procedure, the functional results achieved in our sample are compatible with an active life, allowing most of the patients included in the study to fit the requirements of Portuguese legislation for driving light vehicles, namely at the level of the binocular visual field. These results highlight the role of PRP in the management of diabetic retinopathy in an era with evolving less aggressive laser options.

Acknowledgments

The authors want to acknowledge all the support granted by the Head of the Ophthalmology Department of Centro Hospitalar e Universitário do Porto, Prof. Dr. Pedro Menéres.

Disclosure

The Authors declare that there is no conflict of interest.

References

1. The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. *Am J Ophthalmol*. 1976;81 (4):383–396. doi:10.1016/0002-9394(76)90292-0
2. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. *Ophthalmology*. 1991;98(5):766–785. doi:10.1016/S0161-6420(13) 38011-7
3. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. *Ophthalmology*. 1981;88(7):583–600.
4. Diabetic Retinopathy Study Research Group.Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic retinopathy study report no. 5. *Dev Ophthalmol*. 1981;2:248–261.
5. Patz A, Fine S, Finkelstein D. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. *Ophthalmology*. 1978;85(1):82–106. doi:10.1016/S0161-6420(78)35693-1
6. Subash M, Comyn O, Samy A, et al. The effect of multispot laser panretinal photocoagulation on retinal sensitivity and driving eligibility in patients with diabetic retinopathy. *JAMA Ophthalmol*. 2016;134(6):666–672. doi:10.1001/jamaophthalmol.2016.0629
7. Muqit MM, Wakely L, Stanga PE, Henson DB, Ghanchi FD. Effects of conventional argon panretinal laser photocoagulation on retinal nerve fibre layer and driving visual fields in diabetic retinopathy. *Eye (London, England)*. 2010;24(7):1136–1142. doi:10.1038/eye.2009.308
8. Pearson AR, Tanner V, Keightley SJ, Casswell AG. What effect does laser photocoagulation have on driving visual fields in diabetics? *Eye (London, England)*. 1998;12(1):64–68. doi:10.1038/eye.1998.12
9. Buckley SA, Jenkins L, Benjamin L. Fields, DVLC and panretinal photocoagulation. *Eye (London, England)*. 1992;6(6):623–625. doi:10.1038/eye.1992.134
10. Hulbert MF, Vernon SA. Passing the DVLC field regulations following bilateral pan-retinal photocoagulation in diabetics. *Eye (London, England)*. 1992;6(5):456–460. doi:10.1038/eye.1992.96
11. Mackie SW, Webb LA, Hutchison BM, Hammer HM, Barrie T, Walsh G. How much blame can be placed on laser photocoagulation for failure to attain driving standards? *Eye (London, England)*. 1995;9(4):517–525. doi:10.1038/eye.1995.118
12. Williamson TH, George N, Flanagan DW, Norris V, Blamires T. Driving standards: visual fields in diabetic patients after pan-retinal photocoagulation: vision in vehicles III. 1991;265–272.
13. Diário da República.Decreto-lei número 40/2016. Série I ed. Diário da República. [Decree-law number 40/2016. Series 1 ed. Republic Diary]. Portuguese Government; 2016:64.
14. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). *Ophthalmologica*. 2017;237 (4):185–222. doi:10.1159/000458539
15. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. *Eye Vis (Lond)*. 2015;2:17.
16. Nielsen NV. The prevalence of glaucoma and ocular hypertension in type 1 and 2 diabetes mellitus. An epidemiological study of diabetes mellitus on the island of Falster, Denmark. *Acta Ophthalmol (Copenh)*. 1983;61(4):662–672. doi:10.1111/j.1755-3768.1983.tb04357.x
17. Filek R, Hooper P, Sheidow T, et al. Structural and functional changes to the retina and optic nerve following panretinal photocoagulation over a 2-year time period. *Eye (London, England)*. 2017;31 (8):1237–1244. doi:10.1038/eye.2017.66

18. Williamson TH Driving standards visual fields in diabetic patients after panretinal laser photocoagulation. 1991.

19. Mackie SW, Walsh G. Contrast and glare sensitivity in diabetic patients with and without pan-retinal photocoagulation. *Ophthalmic Physiol Opt*. 1998;18(2):173–181. doi:10.1046/j.1475-1313.1998.00339.x

20. Khosla PK, Rao V, Tewari HK, Kumar A. Contrast sensitivity in diabetic retinopathy after panretinal photocoagulation. *Ophthalmic Surg*. 1994;25(8):516–520.

21. Preti RC, Ramirez LM, Monteiro ML, Carra MK, Pelayes DE, Takahashi WY. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial. *Br J Ophthalmol*. 2013;97(7):885–889. doi:10.1136/bjophthalmol-2012-302675

22. Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. *JAMA*. 2015;314(20):2137–2146. doi:10.1001/jama.2015.15217

23. Lin J, Chang JS, Smiddy WE. Cost evaluation of panretinal photocoagulation versus intravitreal ranibizumab for proliferative diabetic retinopathy. *Ophthalmology*. 2016;123(9):1912–1918. doi:10.1016/j.ophtha.2016.05.037

24. Yun SH, Adelman RA. Recent developments in laser treatment of diabetic retinopathy. *Middle East Afr J Ophthalmol*. 2015;22(2):157–163. doi:10.4103/0974-9233.150633